|
Wednesday, January 19, 2022 |
|
Avance Clinical在2022年生物技術展上宣佈為美國擴張進行重大私募股權投資 |
Avance Clinical 是澳大利亞最大的國際生物技術高級合同研究組織 (CRO),已獲得全球私募股權公司 Riverside Company (Riverside) 的重大投資,以支持進一步的區域和全球擴張。該投資對公司的估值超過 2 億美元。 more info >> |
|
Avance Clinical在2022年生物技术展上宣布为美国扩张进行重大私募股权投资 |
Avance Clinical 是澳大利亚最大的国际生物技术高级合同研究组织 (CRO),已获得全球私募股权公司 Riverside Company (Riverside) 的重大投资,以支持进一步的区域和全球扩张。 该投资对公司的估值超过 2 亿美元。 more info >> |
|
Tuesday, January 18, 2022 |
|
Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022 |
Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m. more info >> |
|
Tuesday, October 19, 2021 |
|
Avance Clinical臨床試驗合作申辦方XWPharma正式開啟其XW10508首次人類臨床試驗,研究快速緩解難治性抑鬱症以及慢性疼痛療法 |
Avance Clinical的臨床試驗合作申辦方XWPharma正式宣布其XW10508首次人類臨床試驗進入給藥階段。 XW10508是一種穀氨酸能NMDA抑製劑和AMPA激活劑,作為一種治療難治性抑鬱症以及慢性疼痛的創新型口服藥物,其給藥劑量為每日一次。 XWPharma已經為其註冊專利。 more info >> |
|
Avance Clinical临床试验合作申办方XWPharma正式开启其XW10508首次人类临床试验,研究快速缓解难治性抑郁症以及慢性疼痛疗法 |
Avance Clinical的临床试验合作申办方XWPharma正式宣布其XW10508首次人类临床试验进入给药阶段。XW10508是一种谷氨酸能NMDA抑制剂和AMPA激活剂,作为一种治疗难治性抑郁症以及慢性疼痛的创新型口服药物,其给药剂量为每日一次。XWPharma已经为其注册专利。 more info >> |
|
Avance Clinical Client News: XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain |
Avance Clinical, the largest premium Australian CRO for international biotechs, is pleased to share the news that its client XWPharma Ltd. has announced dosing of subjects in its first-in-human study evaluating XW10508, the Company's novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for the treatment of treatment-resistant depression and chronic pain. more info >> |
|
Thursday, August 12, 2021 |
|
아방스 클리니컬, 고객 가치 리더십 부문에서 프로스트&설리번 2021 아시아-태평양 CRO 최고기업상 수상 |
글로벌 바이오테크로써 호주에서 최대 규모를 자랑하는 프리미엄 임상수탁기관(CRO)인 아방스 클리니컬(Avance Clinical)은 유서 깊은 프로스트&설리번(Frost & Sullivan)의 2021 아시아-태평양 CRO 고객 가치 리더십상을 수상했다. 이번 수상을 통해 프로스트&설리번 아태지역(APAC) CRO 최고기업상을 두 차례 연속 수상하게 되었다. more info >> |
|
Wednesday, August 11, 2021 |
|
Avance Clinical 榮獲 Frost & Sullivan 2021 年亞太地區 CRO 最佳實踐獎,以表彰其客戶價值領導力 |
Avance Clinical 是澳大利亞最大的國際生物技術 CRO,榮獲著名的 Frost & Sullivan 2021 亞太 CRO 客戶價值領導獎,這是 Frost & Sullivan 連續第二次授予該公司亞太 (APAC) CRO 最佳實踐獎。 more info >> |
|
Avance Clinical 荣获 Frost & Sullivan 2021 年亚太地区 CRO 最佳实践奖,以表彰其客户价值领导力 |
Avance Clinical 是澳大利亚最大的国际生物技术 CRO,荣获著名的 Frost & Sullivan 2021 亚太 CRO 客户价值领导奖,这是 Frost & Sullivan 连续第二次授予该公司亚太 (APAC) CRO 最佳实践奖。 more info >> |
|
Tuesday, August 10, 2021 |
|
Avance Clinical Awarded Frost & Sullivan 2021 Asia-Pacific CRO Best Practices Award for Customer Value Leadership |
Avance Clinical, the largest premium Australian CRO for international biotechs, has been awarded the prestigious Frost & Sullivan 2021 Asia-Pacific CRO Customer Value Leadership Award, the second consecutive Asia-Pacific (APAC) CRO Best Practices Award for the company from Frost & Sullivan. more info >> |
|
|
|